submision of Annual Report 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Limited has submitted its Annual Report for FY 2024-25 along with the notice of its 36th Annual General Meeting, scheduled for Wednesday, 24th September 2025 at 11:00 AM via video conferencing. On the financial front, standalone total income fell sharply to Rs. 23,330.02 lakhs from Rs. 4,06,278.78 lakhs in the previous year, while standalone profit after tax dropped to Rs. 153.20 lakhs from Rs. 3,273.02 lakhs; consolidated profit stood at Rs. 212.94 lakhs. The Board has not recommended any dividend, opting to conserve profits for future growth. During the year, the company executed a 3:1 bonus issue (record date 6th July 2024), raised its authorised share capital multiple times (from Rs. 30 crore to Rs. 110 crore), changed its RTA to Bigshare Services, and saw several director resignations and fresh appointments, including a new Chairman. Shareholders will also consider the appointment of Ms. Riddhi Shah as Secretarial Auditor for a 5-year term at the AGM.
The dramatic year-on-year drop in revenue (~94%) and profit (~95%) on a standalone basis is a serious red flag for retail investors and warrants careful review of the full financial statements and management discussion. While the company cites no change in business activity, the sharp decline suggests a major shift in operations, while the bonus issue and capital structure changes indicate active restructuring rather than steady growth.